VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia
Authors:
- R. CaporaleRCR. Caporale
- F. BalestriFBF. Balestri
- S. GavazziSGS. Gavazzi
- J. JimenoJJJ. Jimeno
- A. GrossiAGA. Grossi
Open Access
- 13 July 2005
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 16 (10) , 1667-1674
Abstract
Background: Aplidine (APL) is a marine depsipeptide isolated from the Mediterranean tunicate Aplidium albicans that is under clinical phase II development. In contrast to the lack of bone marrow toxicity reported in phase I/II studies, it has been shown to induce cytotoxicity at very low concentration against lymphoblastic leukemia blast, as well as having an impact in the vascular endothelial growth factor (VEGF)/VEGF receptor 1 loop. Patients and methods: To confirm these findings we investigated APL-related VEGF inhibition and its cytotoxic effect on myeloid leukemic cells lines (K-562, HEL and HL60) and fresh leukemia blasts derived from 30 patients with acute myeloid leukemia (AML). The conventional active 4-demetoxi-daunorubicin (idarubicin; IDA) was included as a positive control. Results: APL was found to be significantly (P < 0.001) more active than IDA in obtaining 50% growth-inhibition in K-562, HEL and HL60 cell lines. Results obtained with AML blast cells were superimposible. ID50 ranged from 0.024 to 0.610 μM for IDA (0.200 ± 0.176) and from 0.001 to 0.108 μM for APL (0.020 ± 0.031). Annexin V tests and cell cycle analysis performed on cell lines confirmed the stronger citotoxic capability of APL as apoptotic inducer and as a G1 blocker. The inhibitory effects of APL on VEGF release and secretion have been confirmed by ELISA tests performed on HEL: the VEGF concentration in cell surnatant was reduced from 169 to 36 pg/ml after 24 h of exposure to a pharmacological concentration of APL. Conclusions: APL harbors a strong in vitro antileukemic activity at a concentration achievable in patients at non-myelotoxic doses. Our data also support the notion of an impact on VEGF secretion. Clinical studies with this new marine-derived compound in relapsed/resistant leukemia are underway.Keywords
This publication has 21 references indexed in Scilit:
- Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidineBritish Journal of Cancer, 2002
- Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid TumorsJournal of Clinical Oncology, 2001
- High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancerAnnals of Oncology, 1999
- Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assaysCancer Chemotherapy and Pharmacology, 1999
- In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cellsBritish Journal of Cancer, 1998
- Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicatesCancer Letters, 1996
- Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743)Drugs of the Future, 1996
- Structure−Activity Relationships of the DidemninsJournal of Medicinal Chemistry, 1996
- Bioactive Compounds from Aquatic and Terrestrial SourcesJournal of Natural Products, 1990
- Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicateJournal of the American Chemical Society, 1981